Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for organ protection in post-acute myocardial infarction cardiogenic shock
ChiCTR1800020367Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of ulinastatin in cardiogenic shock and myocardial infarction (MI) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Tumor necrosis factor-alpha, Interleukin-6 and 7 more. Started Jan 2019; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
cardiogenic shockmyocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR1800020367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020367.